Veru Inc. (VERU) News
Filter VERU News Items
VERU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VERU News Highlights
- For VERU, its 30 day story count is now at 3.
- Over the past 21 days, the trend for VERU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VERU are ARM and FL.
Latest VERU News From Around the Web
Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference to be held at the InterContinental New York, Barcl |
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer--Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus no responses in the standard of care active control arm. On average, enobosarm or active control was given in the 4th line treatment in the metastatic setting which included a prior CDK 4/6 inhibitor combination-- --Overall response rate was 20% for enobosarm monotherapy versus 0% for standard of care active control in patients who had ≤3 lines of prior endocrine therapy in the metasta |
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, |
Veru Inc. (NASDAQ:VERU) Analysts Just Trimmed Their Revenue Forecasts By 25%Today is shaping up negative for Veru Inc. ( NASDAQ:VERU ) shareholders, with the analysts delivering a substantial... |
What You Can Learn From Veru Inc.'s (NASDAQ:VERU) P/SWhen close to half the companies in the Personal Products industry in the United States have price-to-sales ratios (or... |
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue EstimatesVeru Inc. (VERU) delivered earnings and revenue surprises of 35% and 59.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Veru Reports Fiscal 2023 Third Quarter Financial ResultsCompany receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm +/- abemaciclib accelerated approval pathway in metastatic breast cancer, if successful based on new FDA Guidance Company plans to expand sabizabulin Phase 3 confirmatory study to include all types of viral induced lung infections (influenza, RSV and COVID-19) in hospitalized patients requiring supplemental oxygen who are at risk for ARDS Company reported positive separate preclinical data fo |
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for breast cancer and for viral acute respiratory distress syndrome (ARDS), today announced it will host a conference call and audio webcast on Thursday, August 10, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 third quarter financial results and to provide a business update. The audio webcast will be accessible under “Investor Kit” in th |
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal GrantsResearch grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer indications with significant unmet need Aggregate funding for UTHSC exceeds $10M for these oncology drug research programs Veru has rights to further develop and commercialize potential oncology agents generated from this research MIAMI, FL, June 21, 2023 (GLOBE NEWSWIRE) -- The University of Tennessee H |
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory BoardMIAMI, FL, June 01, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced the appointment of Erik Swenson, M.D., a world-renowned pulmonologist specializing in critical care, and Robert Schooley, M.D., an accomplished infectious disease physician and researcher, to its Infectious Disease Scientific Advisory |